CN103446090A - Incarviatone A在抑制肝脏成纤维细胞增殖药物中的应用 - Google Patents
Incarviatone A在抑制肝脏成纤维细胞增殖药物中的应用 Download PDFInfo
- Publication number
- CN103446090A CN103446090A CN2013104321952A CN201310432195A CN103446090A CN 103446090 A CN103446090 A CN 103446090A CN 2013104321952 A CN2013104321952 A CN 2013104321952A CN 201310432195 A CN201310432195 A CN 201310432195A CN 103446090 A CN103446090 A CN 103446090A
- Authority
- CN
- China
- Prior art keywords
- incarviatone
- liver
- fibroblast proliferation
- cell
- proliferation inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 24
- 230000035755 proliferation Effects 0.000 title claims abstract description 16
- 210000004185 liver Anatomy 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- 229940079593 drug Drugs 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 6
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 14
- 206010019668 Hepatic fibrosis Diseases 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004024 hepatic stellate cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001121991 Incarvillea delavayi Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310432195.2A CN103446090B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310432195.2A CN103446090B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103446090A true CN103446090A (zh) | 2013-12-18 |
CN103446090B CN103446090B (zh) | 2015-12-02 |
Family
ID=49729212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310432195.2A Expired - Fee Related CN103446090B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103446090B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021496A2 (en) * | 2003-08-27 | 2005-03-10 | The Trustees Of Columbia University In The City Of New York | Synthesis of derivatives of ginkgolide c |
EP1939166A1 (en) * | 2006-12-19 | 2008-07-02 | InterMed Discovery GmbH | Plants extracts for use in brain modulation |
-
2013
- 2013-09-22 CN CN201310432195.2A patent/CN103446090B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021496A2 (en) * | 2003-08-27 | 2005-03-10 | The Trustees Of Columbia University In The City Of New York | Synthesis of derivatives of ginkgolide c |
EP1939166A1 (en) * | 2006-12-19 | 2008-07-02 | InterMed Discovery GmbH | Plants extracts for use in brain modulation |
Non-Patent Citations (1)
Title |
---|
SHEN,Y.H.ET AL.,: "ncarviatone A,a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi,and its absolute configuration via calculated electronic circular dichroic spectra", 《RSC ADVANCES2》, 31 December 2012 (2012-12-31), pages 4175 - 4180 * |
Also Published As
Publication number | Publication date |
---|---|
CN103446090B (zh) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104095859A (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN104095857A (zh) | 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 | |
CN103251614A (zh) | Aspeverin在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446131A (zh) | Lycojaponicumin B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446132A (zh) | Lycojaponicumin A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446090A (zh) | Incarviatone A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103356533A (zh) | Sarcaboside A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103356523A (zh) | Sarcaboside B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102885808A (zh) | Aphanamixoid A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102861054B (zh) | Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103463074B (zh) | Lycojaponicumin C在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872114A (zh) | Houttuynoid E在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103393697B (zh) | Chukrasone A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872009A (zh) | Eryngiolide A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN106420706A (zh) | Linderolide H 在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103463011B (zh) | Fluevirosines A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872107A (zh) | Houttuynoid A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103536600B (zh) | Phyllanthoid A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103479647A (zh) | Kadcoccitones A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872079A (zh) | Houttuynoid C在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103127149A (zh) | Gypensapogenin B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103315990A (zh) | Nardoaristolones A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872136A (zh) | Houttuynoid B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103372005A (zh) | Chukrasone B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102895240A (zh) | Gypensapogenin A在抑制肝脏成纤维细胞增殖药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Hongli Inventor before: Jiang Chunping Inventor before: Huang Rong |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151103 Address after: 325011, building 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Zhejiang, Wenzhou Applicant after: Wenzhou Chengqiao Technology Co.,Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing guangkangxie Biomedical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181217 Address after: 409000 Baijiahe Road, Zhengyang Industrial Park, Qianjiang District, Chongqing Patentee after: CHONGQING QIANJIANG APENG TECHNOLOGY ENTERPRISE INCUBATOR CO.,LTD. Address before: 325011 room 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Wenzhou, Zhejiang. Patentee before: Wenzhou Chengqiao Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151202 Termination date: 20210922 |